Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults (CoronaVac3CL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04651790
Recruitment Status : Recruiting
First Posted : December 3, 2020
Last Update Posted : March 2, 2021
Sponsor:
Collaborators:
Ministry of Health, Chile
Sinovac Biotech Co., Ltd
Information provided by (Responsible Party):
Pontificia Universidad Catolica de Chile

Brief Summary:
The study will evaluate the efficacy, safety, and immunogenicity of two vaccination schedules of an inactivated vaccine against SARS-CoV-2 infection in adults. Two doses of the vaccine will be administered in a 0,14 and a 0,28-day schedule. Follow-up of safety and efficacy will be assessed for 12 months after the first dose. Immunogenicity will be studied in a subgroup of participants.

Condition or disease Intervention/treatment Phase
Covid19 Vaccines Biological: SARS-CoV-2 inactivated vaccine Phase 3

Detailed Description:
This study will evaluate the efficacy, safety, and immunogenicity of two vaccination schedules of an inactivated vaccine against SARS-CoV-2 infection in adults. This study will be performed in 8 centers. Two schedules will be compared: 0,14 and 0,28-day, at a 1:1 rate. 40% of participants will be 60 or more years-old. Follow-up of safety and efficacy will be assessed for 12 months after administering the first dose. The collection of the data will be through an electronic Case Report Form. Immunogenicity will be studied in a subgroup of participants. Initially, 2,300 volunteers will be recruited.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Multicenter, Phase 3, Randomized Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against SARS-CoV-2 Infection in Adults.
Actual Study Start Date : November 27, 2020
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : March 2022

Arm Intervention/treatment
Active Comparator: Vaccine 0-14
Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 14
Biological: SARS-CoV-2 inactivated vaccine
The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.
Other Name: Coronavac

Experimental: Vaccine 0-28
Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 28
Biological: SARS-CoV-2 inactivated vaccine
The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.
Other Name: Coronavac




Primary Outcome Measures :
  1. Frequency of solicited and unsolicited adverse events that occur during the period of one week after each dose of the vaccine in two vaccination schedules: 0,14 and 0,28 days stratified by age group (18-59 years, and 60 or more years). [ Time Frame: During the first 7 days after each dose of vaccine ]
    The frequency of solicited and unsolicited local and systemic adverse reactions will be registered. This will be measured during the first 7 days after each vaccination. These adverse reactions will be registered according to the age group in adults (18-59 years old) and the elderly (60 years of age or older).

  2. Incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second dose of each vaccination schedule. [ Time Frame: Two weeks after second dose up to one year after first dose ]
    Vaccine efficacy to prevent virologically confirmed COVID-19 two weeks after the second dose of each vaccination schedule will be determined


Secondary Outcome Measures :
  1. Incidence of hospitalized cases of COVID-19 two weeks after the second vaccination of two vaccination schedules [ Time Frame: Since two weeks after the second dose of two vaccination schedules and up 12 month after first dose ]
    The incidence of hospitalized cases of COVID-19 two weeks after the second vaccination of two vaccination schedules will be determined.

  2. Incidence of severe cases or deaths of COVID-19 virologically confirmed two weeks after the second vaccination of two vaccination schedules [ Time Frame: Since two weeks after the second dose up 12 month after first dose ]
    The incidence of severe cases of COVID-19 and deaths, confirmed through PCR, two weeks after the second vaccination of two vaccination schedules, will be determined.

  3. Incidence of adverse reactions to the vaccine, local and systemic, solicited and unsolicited, within the period of four weeks after each vaccination of two vaccination schedules, according to the age, adults (18-59 years old) and elder (>60 years) [ Time Frame: Four weeks after each dose of vaccine in two vaccination schedules ]
    The incidence of adverse reactions to the vaccine, both local and systemic, solicited and unsolicited will be determined. These adverse reactions will be measured within the period of four weeks after each dose of vaccination of two vaccination schedules. These adverse reactions will be registered according to the age group in adult (18-59 years old) and elder (60 years of age or older) subjects

  4. Frequency of severe COVID-19 cases in participants who received at least one dose of vaccine in two vaccination schedules [ Time Frame: Since first dose up to 12 month after ]
    The frequency of severe COVID-19 cases in participants who received at least one dose of vaccine in two vaccination schedules will be determined.

  5. Incidence of serious adverse events (SAE) and adverse events in participants who have received at least one dose of the vaccine, in two vaccination schedules [ Time Frame: Since first dose up to 12 month after ]
    The occurrence of serious adverse events (SAE) and adverse events of special interest in participants who have received at least one dose of the vaccine in two vaccination schedules, will be determined

  6. Percentage of participants that show a significant increase in SARS-CoV-2 specific T cells after vaccination, in two vaccination schedules, determined by flow Cytometry and ELISPOT [ Time Frame: Since first dose up to 4 weeks after second dose ]
    The cellular immune response in a subgroup of participants, before and two and four weeks after the administration of each dose of the vaccine, in two vaccination schedules will be evaluated

  7. Percentage of participants with a significant increase of anti-SARS-CoV-2 antibodies, determined by ELISA [ Time Frame: Since first dose up to 2 weeks after second dose ]
    The presence of anti-SARS-CoV-2 antibodies in a subgroup of participants, before and two weeks after the administration of each dose of the vaccine, in two vaccination schedules, will be evaluated.

  8. Percentage of participants that show a significant increase in SARS-CoV-2 specific T cells after vaccination, determined by flow Cytometry and ELISPOT [ Time Frame: Since first dose up to 4 weeks after second dose ]
    The cellular immune response in a subgroup of participants, before and two and four weeks after the administration of each dose of the vaccine, will be evaluated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adults over 18 years of age.
  • Demonstrate the capacity to understand and sign the Informed Consent document.
  • Agree to comply with the study procedures and visits.

Exclusion Criteria:

  • History of confirmed symptomatic SARS CoV-2 infection.
  • Pregnant (confirmed by positive urine pregnancy test) or breastfeeding females, and/or expressing intention to have sexual practices with reproductive potential without using contraceptive methods in the three months following vaccination.
  • History of an allergic reaction to the vaccine or components of the study vaccine or placebo.
  • Evidence of uncontrolled neurological, cardiac, pulmonary, hepatic, or renal disease, according to anamnesis or physical examination; Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease.
  • Diseases that impair the immune system including neoplasms (except basal cell carcinoma), congenital or acquired immunodeficiencies, and uncontrolled autoimmune diseases not controlled according to anamnesis or physical examination.
  • Behavioral, cognitive, or psychiatric illness that, in the opinion of the principal investigator or his medical representative, affects the participant's ability to understand and collaborate with the requirements of the study protocol.
  • Use of immunosuppressive therapies six months before inclusion in the study or its scheduled use within two years of inclusion. Immunosuppressive therapies will be considered: antineoplastic chemotherapy, radiation therapy, immunosuppressants to induce tolerance to transplants, among others.
  • Have received an immunosuppressive dose of corticosteroids in the last three months before inclusion in the study or scheduled administration of an immunosuppressive dose of corticosteroids for the three months following inclusion in the study. The dose of corticosteroids considered immunosuppressive is equivalent to prednisone at a dose of 20 mg/day for adults for more than a week. The continuous use of topical or nasal corticosteroids is not considered immunosuppressive.
  • History of asplenia, either anatomic or functional.
  • History of bleeding disorders, as deficiency of clotting factors, coagulopathy, platelet dysfunction, or previous history of bleeding or significant bruising after IM injection or venipuncture.
  • Any alcohol or drug abuse in the last 12 months before inclusion in the study that has caused medical, professional, or family problems, as indicated by clinical history.
  • Have received blood products (transfusions or immunoglobulins) in the last three months before inclusion in the study.
  • Have received any vaccine with a live attenuated virus in the last 28 days or inactivated vaccine in the last 14 days before their inclusion in the study, or have immunization scheduled for the first 28 days after their inclusion in the study.
  • Participation in another clinical trial with product administration under investigation during the six months before its inclusion in the study or scheduled participation in another clinical trial in the two years following inclusion.
  • Previous participation in a COVID-19 vaccine evaluation study or previous exposure to a COVID-19 vaccine.
  • Fever (>37.8°C) within 72 hours before vaccination.
  • Any other condition that, in the opinion of the principal investigator or his medical representative, could jeopardize the safety or rights of a potential participant or that would prevent him from complying with this protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04651790


Contacts
Layout table for location contacts
Contact: Katia Abarca, MD +56996797787 katia@med.puc.cl
Contact: Carolina Iturriaga, Nurse +56991292169 citurriaga@med.puc.cl

Locations
Layout table for location information
Chile
Centro de Especialidades Médicas, Red de Salud UC Christus Recruiting
Santiago, RM, Chile, 7770228
Contact: Alvaro Rojas, MD    +56934056808    arojasgo@uc.cl   
Contact: María Soledad Navarrete, Nurse    +56975288431    msnavarr@uc.cl   
Sponsors and Collaborators
Pontificia Universidad Catolica de Chile
Ministry of Health, Chile
Sinovac Biotech Co., Ltd
Investigators
Layout table for investigator information
Study Director: Katia Abarca, MD Pontificia Universidad Catolica de Chile
Study Director: Alexis M Kalergis, PhD Pontificia Universidad Catolica de Chile
Study Director: Susan M Bueno, PhD Pontificia Universidad Catolica de Chile
Study Director: Pablo A González, PhD Pontificia Universidad Catolica de Chile
Layout table for additonal information
Responsible Party: Pontificia Universidad Catolica de Chile
ClinicalTrials.gov Identifier: NCT04651790    
Other Study ID Numbers: 200708006
First Posted: December 3, 2020    Key Record Dates
Last Update Posted: March 2, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Pontificia Universidad Catolica de Chile:
Clinical trials
Covid19
Inactivated vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases